Purpose Similar to other molecularly targeted agents, temsirolimus, an inhibitor of
mammalian target of rapamycin, has shown promising activity in advanced renal cell
carcinoma. However, only a subset of patients appears to derive significant tumor
responses. In an effort to identify potential predictors of response to temsirolimus, tumor
samples from a subset of patients within a randomized phase II trial of temsirolimus in
advanced renal cell carcinoma were studied. Patients and Methods Paraffinembedded …